Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis

Current Pharmaceutical Design

Volumn 20, Issue 1, 2014, Pages 88-100

  Domhan, Sophie ^a,b,c   Schwager, Christian ^a   Wei, Quanxiang ^a   Muschal, Stefan ^a   Sommerer, Claudia ^b   Morath, Christian ^b   Wick, Wolfgang ^a   Maercker, Christian ^a   Debus, Jürgen ^a   Zeier, Martin ^b   Huber, Peter E ^a   Abdollahi, Amir ^a,b,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Expression profiling and transcriptional networks; Fibrogenesis; Immunosuppression; MTOR; RAD001; Rapalogs; Tumor

Indexed keywords

EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MYCOPHENOLIC ACID; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DRUG MECHANISM; EFFECTOR CELL; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; COCULTURE; DRUG ANTAGONISM; GENE EXPRESSION PROFILING; GENETICS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; REAL-TIME POLYMERASE CHAIN REACTION; SYSTEMS BIOLOGY; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME;

EID: 84902659026     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282001140113125549     Document Type: Article

References (43)

1. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-93.
2. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5: 671-88.
3. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-8.
4. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012; 18: 2766-77.
5. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-8.
6. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78: 35-43.
7. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010; 13: 16-28.
8. Abdollahi A, Hlatky L, Huber PE. Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 2005; 8: 59-74.
9. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-63.
10. Abdollahi A, Schwager C, Kleeff J, et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci USA 2007; 104: 12890-5.
11. Domhan S, Muschal S, Schwager C, et al. Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 2008; 7: 1656-68.
12. Abdollahi A, Griggs DW, Zieher H, et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270-9.
13. Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201: 925-35.
14. Domhan S, Ma L, Tai A, Anaya Z, et al. Intercellular communication by exchange of cytoplasmic material via tunneling nano-tube like structures in primary human renal epithelial cells. PLoS One 2011; 6: e21283.
15. Schwager C, Wirkner U, Abdollahi A, Huber PE. TableButler-a Windows based tool for processing large data tables generated with high-throughput methods. BMC Bioinformatics 2009; 10: 235.
16. Sharungbam GD, Schwager C, Chiblak S, et al. Identification of stable endogenous control genes for transcriptional profiling of photon, proton and carbon-ion irradiated cells. Radiat Oncol 2012; 7: 70.
17. Liangos O, Domhan S, Schwager C, et al. Whole blood transcriptomics in cardiac surgery identifies a gene regulatory network connecting ischemia reperfusion with systemic inflammation. PLoS One 2010; 5: e13658.
18. Almog N, Ma L, Schwager C, et al. Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS One 2012; 7: e44001.
19. Girdhani S, Lamont C, Hahnfeldt P, Abdollahi A, Hlatky L. Proton irradiation suppresses angiogenic genes and impairs cell invasion and tumor growth. Radiat Res 2012; 178: 33-45.
20. Domhan S, Zeier M, Abdollahi A. Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transplant 2009; 24: 1097-103.
21. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102: 8204-9.
22. Manegold PC, Paringer C, Kulka U, et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 2008; 14: 892-900.
23. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005; 24: 5414-22.
24. Pore N, Liu S, Haas-Kogan DA, O'Rourke DM, Maity A. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 2003; 63: 236-41.
25. Tanaka K, Babic I, Nathanson D, et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 2011; 1: 524-38.
26. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res 2011; 317: 685-90.
27. Chong CR, Qian DZ, Pan F, et al. Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. J Med Chem 2006; 49: 2677-80.
28. Wu X, Zhong H, Song J, Damoiseaux R, Yang Z, Lin S. Mycophenolic acid is a potent inhibitor of angiogenesis. Arterioscler Thromb Vasc Biol 2006; 26: 2414-6.
29. Wick W, Blaes J, Weiler M. mTORC 2:1 for chemotherapy sensitization in glioblastoma. Cancer Discov 2011; 1: 475-6.
30. Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. Biochem Pharmacol 2008; 75: 1035-44.
31. Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008; 98: 923-30.
32. Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006; 67: 156-8.
33. Porcelli L, Quatrale AE, Mantuano P, et al. Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors. Curr Pharm Des 2013; 19: 918-26.
34. Rao RD, Mladek AC, Lamont JD, et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 2005; 7: 921-9.
35. Wang X, Sun SY. Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets 2009; 13: 1193-203.
36. Dibble CC, Manning BD. A molecular link between AKT regulation and chemotherapeutic response. Cancer Cell 2009; 16: 178-80.
37. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16: 34-44.
38. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-74.
39. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
40. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-68.
41. Mukherjee B, Tomimatsu N, Amancherla K, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATMand DNA-PKCs-mediated DNA damage responses. Neoplasia 2012; 14: 34-43.
42. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-13.
43. Semenza GL. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des 2009; 15: 3839-43.